Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17731568 | 0.81 | ALDH1A1 (0.54) | SMN1; SMN2MAPTLMNAHTTCYP11B1 | |
| SCHEMBL17731466 | 0.81 | L3MBTL1 (0.54) | MEN1KMT2ASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL17731471 | 0.81 | SMN1; SMN2 (0.51) | MEN1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL17731606 | 0.80 | KDM4E (0.50) | MEN1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL31271710 | 0.78 | MEN1 (0.46) | MEN1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL31271942 | 0.78 | JAK2 (0.47) | MEN1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL31271953 | 0.78 | MEN1 (0.43) | MEN1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL31271503 | 0.78 | MEN1 (0.49) | MEN1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL17731532 | 0.78 | POLB (0.50) | SMN1; SMN2LMNAHTTTAAR1IDO1 | |
| SCHEMBL31272139 | 0.78 | FAAH (0.39) | MEN1KMT2ASMN1; SMN2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239882-B2 | Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2019-03-26 | — | — | US | disclosed |
| US-20180282338-A1 | SUBSTITUTED 5-METHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-2-AMINE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC | 2018-10-04 | — | — | US | disclosed |
| EP-3215508-A1 | SUBSTITUTED 5-METHYL-[1, 2, 4]TRIAZOLO [1,5-A) PYRIMIDIN-2-AMINE COMPOUNDS AS PDE2 INHIBITORS | Dart NeuroScience (Cayman) Ltd. (KY) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016073424-A1 | SUBSTITUTED 5-METHYL-[1, 2, 4] TRIAZOLO [1,5-A) PYRIMIDIN-2-AMINE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239882-B2 | Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors | PDE12, PDE2A, PDE3A | MEN1 2189/4885KMT2A 650/4885SMN1; SMN2 16/4885 |
| US-20180282338-A1 | SUBSTITUTED 5-METHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-2-AMINE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE3A | MEN1 2189/4885KMT2A 650/4885SMN1; SMN2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.